

WP 7 Cancer Information and Registries

Roberta De Angelis, MSc, Scientific coordinator iPAAC WP 7
Italian National Institute of Health- Istituto Superiore di Sanità (ISS),IT





TOPICS OVERVIEW



1. General introduction on WP7 activities (R. De Angelis)

State of play of the different Tasks

- 2. Task 1-4 Piloting the integration of data sources (R. De Angelis)
- 3. Task 5 ICT model in the Czech Rep to integrate multiple data sources to the National CR (O. Majek)
- 4. Task 6- Cancer prevalence in Europe (E. Demuru)



WP-7 OBJECTIVES



Actions to enhance population-based cancer information systems to better support evidence-based comprehensive cancer care

1. To advance current registries datasets Tasks 1-5

Piloting the *integration with administrative health data sources* to derive key indicators for cancer care management

2. To better use current registries datasets Task 6

Promoting the use of indicators on cancer prevalence in Europe at MS level



FROM EPAAC and CANCON to iPAAC



Previous JA recommendations





European Cancer Information System (ECIS)

Better coordination to overcome fragmentation of information in Europe and deliver comprehensive indicators on cancer incidence, mortality, survival and **prevalence**

Cancer survivorship care

Collecting data on clinical follow up and quality of life of cancer survivors at the population level to improve survivorship and prevent late effects



Need to enhance cancer information on the whole patients pathway



POTENTIAL OF POPULATION-BASED CANCER REGISTRIES





- well-established surveillance systems
- objective, accurate, representative
- indispensable for epidemiological research, for cancer plans and quality of care assessment




- ✓ partial population and scarce timeliness
- ✓ poor information on care details (stage, first treatment, type of surgery,...)¹
- poor information after care (late effects & comorbidity) ¹

Room to improve the potential of cancer registries and to strengthen their support to comprehensive cancer control



INTEGRATION WITH ADMINISTRATIVE AND HEALTH DATABASES





AIM: Methods and means to advance registry data through linkage with current health data flows



TASKS 2-5 EXPECTED OUTCOMES



Standardised procedures and requisites to integrate administrative health data with European cancer registries datasets and derive more advanced indicators

Three pilots in Europe

Task 2 – Quality of Care - care pathways and adherence to standard guidelines - *INT- M. Sant*

Task 3 – Costs of Care - direct costs related to diagnosis, care and follow up along the entire disease pathway

ISS- S. Francisci

Task 4 – Long-term clinical follow up - late effects in Adolescents and Young Adults (AYAs) cancer survivors - INT- A. Trama

Task 5 Pilot in the Czech Republic

Complex ICT model integrating the
National Cancer Registry with multiple data
sources to support cancer care
management

MUNI-UZIS – L. Dusek



WP-7 OBJECTIVES



Actions to enhance population-based cancer information systems to better support evidence-based comprehensive cancer care

1. To advance current registries datasets Task 1-5

Piloting the *integration with administrative health data sources* to derive key indicators for cancer care management

2. To better use current registries datasets Task 6

Promoting the use of indicators on *cancer prevalence* in Europe at MS level



WHY PREVALENCE INDICATORS?

CEBP Annual Report



- Cancer survivors, a growing population in ageing societies
- Increasing costs of therapies challenges the sustainability
- Indicators quantifying health care demand are needed BUT are not systematically available in Europe

Published OnlineFirst March 27, 2013; DOI: 10.1158/1055-9965.EPI-12-1356


Cane Epidemiolo Biomark & Preventi

Cancer Survivors in the United States: Prevalence across the Survivorship Trajectory and Implications for Care

Janet S. de Moor¹, Angela B. Mariotto², Carla Parry³, Catherine M. Alfano¹, Lynne Padgett³, Erin E. Kent⁴, Laura Forsythe^{5,6}, Steve Scoppa⁷, Mark Hachey⁷, and Julia H. Rowland¹

10 15+ years 10-<15 years 15-<10 years 1-<5 years 1-<5

INCREASING CANCER PREVALENCE IN ITALY PROJECTIONS TO 2020 Guzzinati et al. BMC Cancer 2018





TASK 6: EXPECTED OUTCOMES




- Promoting dissemination and use of comprehensive indicators on cancer prevalence in Europe at MS level (ISS, R. De Angelis)
 - by disease duration and complete (observed + un-observed)
 - time projections (timeliness)
 - prevalence by phase of care (initial, terminal, intermediate)
 - prevalence of cured patients, cure fraction and time to cure
 - life expectancy of cancer survivors
- Integrate the European Cancer Information System (ECIS)
 managed by ENCR-JRC with systematic cancer prevalence
 indicators by country/region in Europe



DATA FROM THE EUROCARE-6 STUDY





29 Countries23 National Registries

102
Cancer
Registries
- Adult cases -

coverage (79 CRs)
France, Germany, Italy,

6 Countries with local

Portugal, Spain, Switzerland

WP-7 OUTCOMES FOR THE ROAD MAP



1. ADVANCING REGISTRIES DATASETS

Task 1 Mapping data sources to integrate registries data

Task2 Pilot study on cancer pathways

Task3 Pilot study on cancer costs

Task 4 Pilot on long term follow up of cancer survivors Task 5
Piloting
integration
of data
sources in a
ICT model

2. BETTER USING REGISTRIES DATASETS

Task 6

info canc

WP 7 Road Map

Recommendations and strategies to implement policies to advance cancer information systems in MS



WP 7 – CANCER INFORMATION AND REGISTRIES



KEY DELIVERABLES & MILESTONES IN THE FIRST HALF OF THE IPAAC JA

- Task 1 Survey to map administrative data sources available to integrate cancer registry data
- Task 2-4 Workshop to agree on the study protocols of the pilots to integrate data sources with registry data
- Task 5- Legal background approved for National ICT model integrating multiple data sources in the Czech Republic
- Task 6 Validated methodology to derive first core cancer prevalence indicators by country in Europe

2. KEY DELIVERABLES & MILESTONES IN THE SECOND HALF OF THE IPAAC JA


- Task 2-4 Standardised procedures to derive comparable indicators on quality of care, direct costs of care, and disease patterns of AYA survivors, through integration with administrative data sources (3 rd milestone meeting)
- Task 5 Implementation and validation of the National Health Information system integrating epidemiological, administrative and clinical records to support quality improvement in cancer care in the Czech Republic
- Task 6 Systematic delivery of up-to-date population-based indicators on cancer prevalence in MS to boost the European Cancer Information System (ECIS)



WP-7 PARTNERSHIP: 17 COUNTRIES



Staff effort per applicant (%)



3. Collaborating partners and stakeholders

- European Network of Cancer Registries (ENCR) and National Associations (ReDeCAN, AIRTUM)
- Joint Research Center (JRC) European Commission
- Patients Associations
 - ECPC, Pancreatic Cancer Europe-PCE
- National Research Institutions and Universities
 - Tor Vergata, CNR (IT)
 - Tampere (FI)

WP 7 – CANCER INFORMATION AND REGISTRIES



4. KEY ISSUES TO BE DISCUSSED WITH COLLABORATING PARTNERS

- Common standards and procedures to advance registry-based information on the whole cancer pathway
- Legal requirements to access additional data sources and enhance the scope of cancer registration
- How to increase the interoperability between epidemiological, administrative, clinical data sources



Tasks 1-4

Advancing registries datasets through integration with multiple data sources

- G. Tagliabue, M. Sant, A. Trama Istituto Nazionale dei Tumori, Milan IT (INT)
- S. Francisci, R. De Angelis Istituto Superiore di Sanità, Rome IT (ISS)





WP 7 - TASKS 1-4



KEY DELIVERABLES & MILESTONES IN THE FIRST HALF OF THE IPAAC JA



- Survey to map data sources available to cancer registries in Europe
- Final Report / November 2019



TASK 1: MAPPING DATA SOURCES



SURVEY QUESTIONNAIRE on accessible data flows and on legal procedures to access, link, share patients microdata

4. DATA SOURCES

a) INFORMATION ON DATA SOURCES IN USE TO THE CR (indicate which are used by the CR and specify their characteristics)

LEGEND:

- [@] Relevance. Please indicate in which percentage the source contributes to the definition of CR cases. If not routinely calculated, please indicate an estimated value, based on your experience.
- [#] Completeness. Please indicate the percentage of completeness of the source, i.e. in which percentage all the events monitored by the source that occur to a patient are included in the data flow received by the CR. For example, suppose a patient experiences 20 hospitalizations, in which percentage are they recorded in the Hospital Discharge flow ? If not routinely calculated, please indicate an estimated value, based on your experience.
- [§] Pathway. Is this data source relevant to reconstruct the complete therapeutic pathway of patients?
- [+] Linkage feasibility. Is it possible for the registry to identify patients' records in the data source through linkage with their tumour cases?
- [*] Transmission to iPAAC. Are you legally permitted to provide case data linked to other data sources in anonymized format to the iPAAC study? If you answered No please specify in Section 5 SUGGESTION Box if it is possible to overcome the ban through appropriate procedures and how the iPAAC project can help you.
- [^] Record Track. Please provide the record track file of the data source in English (see the example given in Section 6) and indicate here its name. Accepted file formats are: .txt, .doc(v.), xls(x), csv.

		Availability		U	sability and Quali	ty	Linkage Feasibility	Transmission to	Record Truck file name
Source Name	From Year	To Year	Type of diseases	Relevance (in %)	Completeness (in %)	Pathway (in %)	.,	iPAAC	(4)
				[@]	[#]	(5)	[+]	[*]	[^]
I. Hospital discharges			all diseases			□Yes □No	☐Yes In house ☐No	□Yes □No	
i. Inospital discharges			only cancer			2163 2140	☐Yes, externally	□163 □140	
II. Private hospital / Clinical facilities			 all diseases 			□Yes □No	☐Yes In house ☐No	□Yes □No	
ii. Private nospital / Clinical facilities	***************************************	***************************************	only cancer			Lifes Livo	☐Yes, externally	□res □reo	
III. Hospital oncology registries			all diseases			□Yes □No	☐Yes In house ☐No	□Yes □No	
III. Hospital oncology registries	***************************************		only cancer			Lifes Livo	☐Yes, externally	□162 □140	
IV Dathalam laboratorias			☐ all diseases			□Yes □No	☐Yes In house ☐No	□Yes □No	
IV. Pathology laboratories			only cancer			Ties Tivo	☐Yes, externally	Files Fileo	

AIM → to support pilot studies



To assess the feasibility of registry participation

To define the protocols for data integration


Cancer care pathways

Cancer care costs

Long term survivorship

TASK 1 - SURVEY RESULTS





33 registries were contacted

27 CRs (82%) from 14 countries replied

Data sources file formats

17 CRs (63%) supplied the structure of data sources

3 CRs (11%) did not supply for complex structure 7 CRs (26%) did not supply for other reasons

Data sharing with iPAAC

17 CRs (63%) legally authorised to link and share data

Data sources that can be shared:

- Screening programmes data (93%)
- Death certificates (71%)
- Hospital discharges (65%)
- Pathology laboratories records (57%)



TASK 1: HIGHLIGHTS



There is considerable variability between countries

- In most countries the integration is feasible (varying data flows spectrum)
- In some countries not all relevant data sources are electronic
- All pathologies occurring to cancer patients are not always accessible (<u>lack of legal</u> mandate). Accessibility reflects registries' institutional mandate.
- Accessing and sharing data is usually possible upon <u>specific permissions or</u> <u>agreements</u> (varying complexity and time needed)



WP 7 – TASKS 1-4



KEY DELIVERABLES & MILESTONES IN THE FIRST HALF OF THE IPAAC JA

Task 1

- Survey to map data sources available to cancer registries in Europe
- Final Report / November 2019

Tasks 2-4

- Study protocols agreed in the 2° Milestone Meeting / March 2019
- Specific agreements with participating registries

Tasks 2-4

Internal Report defining pilot protocols /July 2019




TASKS 2-4 : PILOT PROTOCOLS STUDY DESIGN





Tasks 2-3
CROSS SECTIONAL DESIGN
Prevalent cases data are linked
to detect all events occurring 2-y
before and 1-y after the index
date

Task 4
LONGITUDINAL DESIGN
AYAs survivors cohorts are
linked prospectively to detect
all events marking late effects



TASKS 2-4 : PILOT PROTOCOLS INDEX TUMOURS



Tasks 2-3: Cancer-specific indicators & procedures

- Colon (ICDO-3 C18)
- Rectum (C19-20)
- Skin melanoma (C44, morphology codes 8720-8790)
- Pancreas (C25)

Tasks 4: no cancer selections for AYA survivors



TASKS 2-4: PILOT PROTOCOLS TARGET INDICATORS



Task 7.2

- Indicators of standard care
 - Example for <u>rectal cancer</u>: % screen detected, % endoscopy with biopsy, % neo-adjuvant radiotherapy in resected stage III, % metastatic treated with targeted therapy, peri-operative mortality (30/90 days)
- Indicators of quality of care at the end of life

Task 7.3

- Monthly and annual average costs (overall and by phase of care);
- Total annual cost;
- Percentage of patients receiving at least one surgery treatment;
- Percentage of patients in initial phase of care receiving at least one chemotherapy
- Time occurring between surgery and chemotherapy.

Task 7.4

- Standardized incidence ratio (SIR) of cancer and other chronic diseases;
- Standardized mortality ratio (SMR);
- Risk ratio of attaining a low education level, of not getting married, of being financially dependent, of being unemployed.



TASKS 2-4: PILOT PROTOCOLS DATA REQUIREMENTS FOR EACH INDICATOR



Indicators	Data required	Data source
SIR of multiple cancers	multiple primary malignancies of AYA cancer survivors and of the not-AYA cancer population	Cancer registry database
SIR of chronic diseases	Information on cardiovascular, respiratory, endocrine diseases on infertility and pregnancy problems for the AYA cancer survivors and for the cancer-free population	clinical discharge records: hospitalisation for a specific d proxy of the disease occurrance (standardised hospitalis ratio).
SMR	Mortality (including cause specific mortality) for AYA cancer survivors and for the cancer-free population	Mortality register
RR of low education	Information on the atteined education for AYA cancer survivors and for the cancer free population	Census. Education ISCED classification
RR of not being married	Information on marital status for AYA cancer survivors and for the cancer-free population	Census. Marital status classified as: married; not married divorced; widowed;single
RR of being unemplyed or being in an unskilled working class	Information on occupational conditions and occupational class for AYA cancer survivors and for the cancer-free population	Census. occupational conditions classified as Employed Unemployed/looking for first occupation, Housewife, Stud Retired; occupational class classified as Bourgeoisie, Micclass, Self-employed with employees, Self-employed with employees, Skilled working class, Unskilled working class
RR of using social/financials benefit	Information on the use of social/financial benefit status for AYA cancer survivors and for the cancer-free population	In Italy INAIL/INPS (collaboration in progress). In other countries to be defined.

NEXT STEPS



Linkage Analysis Results Validation Road Map

- 1. Linkage with available data sources
- 2. Analysis: quality checks, estimation and validation of the target indicators
 - Centralised vs de-centralised analysis option
 - Participating registries from 7 countries: BE, NO, IT, SP, PT, PL, GR
- 3. Third Milestone Meeting to discuss Pilots' results (Sept 2020)
- 4. Road Map deliverable
 - Recommended actions and standardised procedures to integrate CRs data